ITP
ALNY icon

Iron Triangle Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Iron Triangle Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-29,339
Closed -$9.57M – 26
2025
Q2 		$9.57M Sell
29,339
-36,070
-55% -$9.98M 1.47% 25
2025
Q1 		$17.7M Buy
+65,409
New +$16.8M 2.78% 16
2022
Q4 		– Sell
-80,000
Closed -$16M – 27
2022
Q3 		$16M Buy
+80,000
New +$15.3M 2.8% 21

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Iron Triangle Partners's ALNY Position: Q3 2025 in Review

Iron Triangle Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2025, closing a stake of 29,339 shares — an estimated $9.57M sold.

Iron Triangle Partners first reported a position in ALNY in Q3 2022 and held it in 3 quarters. The position peaked at $17.7M in Q1 2025. 823 funds tracked by Wall St. Rank hold ALNY as of Q3 2025.

  • Iron Triangle Partners reported no remaining Alnylam Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Iron Triangle Partners sold 29,339 Alnylam Pharmaceuticals shares in Q3 2025, an estimated $9.57M.
  • Iron Triangle Partners first reported a position in Alnylam Pharmaceuticals in Q3 2022 and held it in 3 quarters.
  • Iron Triangle Partners's Alnylam Pharmaceuticals position peaked at $17.7M in Q1 2025.
  • 823 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2025.

Based on Iron Triangle Partners's 13F filing for Q3 2025, filed 14 Nov 2025.